PharmaResearch, “Rejuran's Entry into Vietnam in Full Swing”
PharmaResearch, “Rejuran's Entry into Vietnam in Full Swing”
  • Cho Eun, Reporter
  • 승인 2024.05.21 23:41
  • 수정 2024.05.21 23:41
  • 댓글 0
이 기사를 공유합니다

Launched in 2014…Entered over 30 countries including the US

PharmaResearch announced on May 21st that it has officially entered the Vietnamese market with the 'Rejuran Launching Symposium' held at the InterContinental, Vietnam on May 17th. 

More than 400 Vietnamese aesthetic professionals and medical staff attended the symposium, checking out the excellence of Rejuran and having in-depth discussions on its treatment methods. 

Rejuran is a medical device for the improvement of facial wrinkles made with polynucleotides (PN), a salmon-derived regenerative material using DOT (DNA Fragment Optimizing Technology) technology. 

At the symposium, Rejuran key doctor Michael J. Kim and five Vietnamese physicians, including Dr Nguyen Vu Hoang, Dr Pham Thi Uyen Nhi, Dr Tran Nguyen Anh Tu, and Dr Nguyen Quang Minh, explained the effectiveness and safety of Rejuran. 

“We are pleased to introduce Rejuran's technology to the Vietnamese market,” said a representative from PharmaResearch. “Through this launch, we will not only expand our market share in the Vietnamese aesthetics market in earnest, but also solidify the Rejuran's position by providing aesthetic solutions to the global market.”

Since its launch in 2014, Rejuran has been registered and sold in more than 30 countries, including the United States, China, and Japan.

[WIKI KOREA=Cho Eun, Reporter]

기자가 쓴 기사

  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2024 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 :